| Year |
Citation |
Score |
| 2010 |
Chirch LM, Steigbigel RT. Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection. Infection and Drug Resistance. 3: 15-23. PMID 21694890 |
0.344 |
|
| 2010 |
Rockstroh J, Eron J, Cooper D, Steigbigel R, Nguyen, Xu X, Wan H, Rodgers A, Miller M, Leavitt R, Sklar P, Teppler H. Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV Journal of the International Aids Society. 13: 130. DOI: 10.1186/1758-2652-13-S4-P130 |
0.386 |
|
| 2009 |
Chirch LM, Morrison S, Steigbigel RT. Treatment of HIV infection with raltegravir. Expert Opinion On Pharmacotherapy. 10: 1203-11. PMID 19385721 DOI: 10.1517/14656560902911488 |
0.387 |
|
| 2008 |
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. The New England Journal of Medicine. 359: 355-65. PMID 18650513 DOI: 10.1056/NEJMoa0708978 |
0.37 |
|
| 2008 |
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. The New England Journal of Medicine. 359: 339-54. PMID 18650512 DOI: 10.1056/NEJMoa0708975 |
0.409 |
|
| 2007 |
Go R, Steigbigel R. Interleukin 2 and HIV RNA Levels. Archives of Internal Medicine. 167: 2144-5; author reply. PMID 17954814 DOI: 10.1001/Archinte.167.19.2144-B |
0.382 |
|
| 2007 |
Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H, ... ... Steigbigel R, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study Journal of Acquired Immune Deficiency Syndromes. 46: 125-133. PMID 17721395 DOI: 10.1097/QAI.0b013e318157131c |
0.43 |
|
| 2007 |
Fu TM, Dubey SA, Mehrotra DV, Freed DC, Trigona WL, Adams-Muhler L, Clair JH, Evans TG, Steigbigel R, Jacobson JM, Goepfert PA, Mulligan MJ, Kalams SA, Rinaldo C, Zhu L, et al. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. Aids Research and Human Retroviruses. 23: 67-76. PMID 17263635 DOI: 10.1089/Aid.2006.0114 |
0.447 |
|
| 2006 |
Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. Journal of Acquired Immune Deficiency Syndromes (1999). 43: 509-15. PMID 17133211 DOI: 10.1097/QAI.0b013e31802b4956 |
0.437 |
|
| 2006 |
Chirch LM, Feiner J, Go R, Mynarcik D, McNurlan M, Gelato M, Steigbigel R. Osteopenia in patients with HIV infection is not associated with elevated sTNFR2 levels. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 43: 1084-5. PMID 16983627 DOI: 10.1086/507901 |
0.456 |
|
| 2003 |
Hirsch MS, Steigbigel RT, Staszewski S, McMahon D, Fischl MA, Hirschel B, Squires K, DiNubile MJ, Harvey CM, Chen J, Leavitt RY. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 37: 1119-24. PMID 14523778 DOI: 10.1086/378063 |
0.378 |
|
| 2003 |
Tussey LG, Nair US, Bachinsky M, Edwards BH, Bakari J, Grimm K, Joyce J, Vessey R, Steigbigel R, Robertson MN, Shiver JW, Goepfert PA. Antigen burden is major determinant of human immunodeficiency virus-specific CD8+ T cell maturation state: potential implications for therapeutic immunization. The Journal of Infectious Diseases. 187: 364-74. PMID 12552420 DOI: 10.1086/367707 |
0.418 |
|
| 2002 |
Moss RB, Wallace MR, Steigbigel RT, Morrison SA, Giermakowska WK, Nardo CJ, Diveley JP, Carlo DJ. Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination. Clinical and Experimental Immunology. 128: 359-64. PMID 11985528 DOI: 10.1046/j.1365-2249.2002.01835.x |
0.423 |
|
| 2001 |
Dubé MP, Mynarcik DC, Steigbigel RT, McNurlan MA, Gelato MC. Lipodystrophy and insulin resistance in patients with HIV [1] (multiple letters) Journal of Acquired Immune Deficiency Syndromes. 27: 506-507. PMID 11511829 DOI: 10.1097/00126334-200108150-00013 |
0.313 |
|
| 2000 |
Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy Journal of Acquired Immune Deficiency Syndromes. 25: 312-321. PMID 11114831 |
0.304 |
|
| 1999 |
Mynarcik DC, Frost RA, Lang CH, DeCristofaro K, McNurlan MA, Garlick PJ, Steigbigel RT, Fuhrer J, Ahnn S, Gelato MC. Insulin-like growth factor system in patients with HIV infection: Effect of exogenous growth hormone administration Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 22: 49-55. PMID 10534146 DOI: 10.1097/00042560-199909010-00006 |
0.328 |
|
| 1999 |
Hirsch M, Steigbigel R, Staszewski S, Mellors J, Scerpella E, Hirschel B, Lange J, Squires K, Rawlins S, Meibohm A, Leavitt R. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. The Journal of Infectious Diseases. 180: 659-65. PMID 10438352 DOI: 10.1086/314948 |
0.437 |
|
| 1998 |
Morrison SA, Pearson SL, Steigbigel RT. Anti-F(ab')2 antibody in HIV type 1 infection: Relationship to hypergammaglobulinemia and to antibody specific to the V3 loop region of glycoprotein 120 Aids Research and Human Retroviruses. 14: 491-498. PMID 9566551 |
0.351 |
|
| 1997 |
McNurlan MA, Garlick PJ, Steigbigel RT, DeCristofaro KA, Frost RA, Lang CH, Johnson RW, Santasier AM, Cabahug CJ, Fuhrer J, Gelato MC. Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease Journal of Clinical Investigation. 100: 2125-2132. PMID 9329979 DOI: 10.1172/Jci119747 |
0.301 |
|
| 1997 |
Morrison SA, Govek EE, Steigbigel RT. Effects of potent antiretroviral therapy on hypergammaglobulinemia (HyG) and anti-gp120 antibody (Ab) Clinical Infectious Diseases. 25: 393. |
0.37 |
|
| 1996 |
Moorjani H, Craddock BP, Morrison SA, Steigbigel RT. Impairment of phagosome-lysosome fusion in HIV-1-infected macrophages Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 13: 18-22. PMID 8797681 |
0.37 |
|
| 1996 |
Cohen AJ, Steigbigel RT. Eosinophilia in patients infected with human immunodeficiency virus Journal of Infectious Diseases. 174: 615-618. PMID 8769622 DOI: 10.1093/INFDIS/174.3.615 |
0.42 |
|
| 1996 |
Lake-Bakaar G, Elsakr M, Hagag N, Lyubsky S, Ahuja J, Craddock B, Steigbigel RT. Changes in parietal cell structure and function in HIV disease Digestive Diseases and Sciences. 41: 1398-1408. PMID 8689917 DOI: 10.1007/BF02088565 |
0.375 |
|
| 1996 |
Handley MA, Steigbigel RT, Morrison SA. A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages. Journal of Virology. 70: 4451-6. PMID 8676469 |
0.364 |
|
| 1996 |
McNurlan M, Garlick P, DeCristofaro K, Froste R, Lang C, Steigbigel R, Fuhrer J, Gelato M. O.16 Growth hormone (GH) stimulates albumin but notmuscle synthesis in HIV+ individuals Clinical Nutrition. 15: 5. DOI: 10.1016/S0261-5614(96)80063-X |
0.348 |
|
| 1995 |
Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, Cohn J, Novak R, Mcmahon D, Fauci AS. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue Proceedings of the National Academy of Sciences of the United States of America. 92: 6017-6021. PMID 7597072 DOI: 10.1073/pnas.92.13.6017 |
0.303 |
|
| 1994 |
Nuovo GJ, Becker J, Burk MW, Margiotta M, Fuhrer J, Steigbigel RT. In situ detection of PCR-amplified HIV-1 nucleic acids in lymph nodes and peripheral blood in patients with asymptomatic HIV-1 infection and advanced-stage AIDS Journal of Acquired Immune Deficiency Syndromes. 7: 916-923. PMID 7914231 |
0.311 |
|
| 1993 |
Cohen AJ, Peerschke EIB, Steigbigel RT. A comparison of the Coulter STKS, Coulter S+IV, and manual analysis of white blood cell differential counts in a human immunodeficiency virus- infected population American Journal of Clinical Pathology. 100: 611-617. PMID 8249907 |
0.387 |
|
| 1993 |
Suzuki K, Craddock BP, Okamoto N, Kano T, Steigbigel RT. Detection of human immunodeficiency virus (HIV) by colorimetric assay for reverse transcriptase activity on magnetic beads Biotechnology and Applied Biochemistry. 18. PMID 7691079 DOI: 10.1111/j.1470-8744.1993.tb00254.x |
0.311 |
|
| 1993 |
Suzuki K, Craddock BP, Kano T, Steigbigel RT. Colorimetric reverse transcriptase assay for HIV-1 Journal of Virological Methods. 41: 21-28. PMID 7679395 DOI: 10.1016/0166-0934(93)90159-O |
0.332 |
|
| 1993 |
Suzuki K, Craddock BP, Okamoto N, Kano T, Steigbigel RT. Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptase Journal of Virological Methods. 44: 189-198. PMID 7505283 DOI: 10.1016/0166-0934(93)90054-U |
0.326 |
|
| Show low-probability matches. |